Implication of BAG5 downregulation in metabolic reprogramming of cisplatin-resistant ovarian cancer cells via mTORC2 signaling pathway

Ovarian cancer is the most frequent cause of gynecologic malignancies associated death. Primary or acquired cisplatin resistance frequently occurred during ovarian therapy. Cancer stem cells (CSC) tend to form minimal residual disease after chemotherapy and are implicated in relapse. The ability reprogram their metabolism has recently been related with maintenance CSC chemotherapies. current study found that BAG5 expression was decreased cisplatin-resistant clinical tissues. Our data demonstrated knockdown metabolic reprogramming cell (CSC)-like features via regulation Rictor subsequent mTORC2 signaling pathway. In addition, Bcl6 upregulation responsible for repression transactivation recruitment on promoter cancer. also reverse correlations between Bcl6, serous adenocarcinoma Collectively, identified implication Bcl6/BAG5/Rictor-mTORC2 pathway reprograming CSC-like cells. Therefore, further studies mechanism underlying characteristics may contribute establishment novel therapeutic strategy cisplatin-resistance. • promoter.